Skip to main content

Table 1 Baseline characteristics

From: Influence on ICU course, outcome and costs for lung transplantation after implementation of the new Swiss transplantation law

 

Pre (n = 42)

Post (n = 37)

P value

Women

21 (50.0%)

18 (48.6%)

 

Men

21 (50.0%)

19 (51.4%)

 

Age (years)

49 (17–69)

54 (13–67)

0.34

Weight (kg)

54 (36–90)

61 (40–100)

0.008

Height (m)

1.65 (1.42–1.83)

1.65 (1.55–1.87)

0.37

BMI (kg/m2)

18.9 (14.8–34.0)

22.1 (16.0–61.0)

0.002

Creatinine (μM)

69 (29–96)

61 (31–136)

0.96

CMV positivity

18 (42.9%)

15 (40.5%)

0.84

Pulmonary hypertensiona

4 (9.5%)

5 (13.5%)

0.58

Diagnosis

  

0.57

   CF

18 (42.9%)

11 (29.7%)

 

   COPD

9 (21.4%)

10 (27.0%)

 

   AAT

2 (4.8%)

3 (8.1%)

 

   IPF

9 (21.4%)

11 (29.7%)

 

   PAH

1 (2.4%)

0 (0%)

 

   Other

3 (7.1%)

2 (5.4%)

 

Location before TPL

  

0.26

  Home

34 (81.0%)

29 (78.4%)

 

  Hospital, ward

6 (14.3%)

4 (10.8%)

 

  Hospital, ICU

2 (4.7%)

4 (10.8%)

 

ECMO support before TPL

0 (0%)

3 (8.1%)

0.06

Mechanical ventilation before TPL

1 (4.8%)

4 (10.8%)

0.31

  1. Data expressed as median (range) or number (percentage).
  2. AAT, α1-antitrypsin-deficiency emphysema; BMI, body mass index; CF, cystic fibrosis; CMV, cytomegalovirus; COPD, chronic obstructive lung disease; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; IPF, idiopathic pulmonary fibrosis; PAH, pulmonary arterial hypertension; TPL, transplantation.
  3. aAssessed by transthoracic echocardiography (pulmonary arterial systolic pressure > 50 mmHg) [8].